Cellebrite DI (NASDAQ:CLBT) Releases Earnings Results, Beats Estimates By $0.06 EPS

Cellebrite DI (NASDAQ:CLBT) posted its quarterly earnings data on Thursday. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.05 by $0.06, FiscalAI reports. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%. The firm had revenue of $131.14 million during the quarter, compared to analyst estimates of $131.87 million.

Here are the key takeaways from Cellebrite DI’s conference call:

• Q2 ARR and revenue fell short of expectations, with ARR rising 21% to $508 million but missing the low end of guidance. Several large government transactions slipped because of new procurement, foreign-entity permitting, and cloud/AI approval requirements.
• Cellebrite reduced its full-year 2026 outlook to $550 million–$560 million of ARR and $555 million–$561 million of revenue, citing slower Inseyets pricing and expansion, elongated deal cycles, and greater caution around large transactions.
• The company raised its full-year adjusted EBITDA outlook to $153 million–$159 million, or a 28% margin, while maintaining confidence in improving free cash flow as headcount remains essentially flat and FX headwinds eventually ease.
• New products are gaining traction: growth products contributed 25% of the sequential ARR increase, Genesis generated about $400,000 of ARR shortly after its launch, and Guardian secured a first major FedRAMP deal with a seven-figure initial order.
• Shiv Ramji became CEO effective immediately in an accelerated succession from Tom Hogan, reflecting the board’s preference for a product-centric leader focused on cloud-native platforms and AI; Cellebrite said the transition has the support of the management team.

Cellebrite DI Stock Performance

NASDAQ CLBT traded up $0.34 during trading hours on Friday, reaching $11.14. The stock had a trading volume of 7,844,977 shares, compared to its average volume of 2,143,691. The stock has a fifty day moving average of $14.52 and a 200 day moving average of $14.05. The stock has a market cap of $2.78 billion, a P/E ratio of 39.79, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98.

Cellebrite DI News Summary

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday. Lake Street Capital decreased their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings cut shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research report on Friday. Finally, DA Davidson cut their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.70.

Insiders Place Their Bets

In other Cellebrite DI news, CEO Thomas E. Hogan sold 139,713 shares of Cellebrite DI stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares in the company, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO David Barter sold 41,734 shares of the company’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the sale, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This trade represents a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 297,934 shares of company stock valued at $4,631,972. 5.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Cellebrite DI

Hedge funds have recently added to or reduced their stakes in the business. Mangrove Partners IM LLC purchased a new position in shares of Cellebrite DI during the 4th quarter valued at approximately $230,000. Virtus Advisers LLC boosted its holdings in Cellebrite DI by 297.7% during the third quarter. Virtus Advisers LLC now owns 12,954 shares of the company’s stock worth $240,000 after buying an additional 9,697 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in Cellebrite DI during the third quarter worth $386,000. Amundi acquired a new stake in Cellebrite DI during the third quarter valued at $264,000. Finally, SkyView Investment Advisors LLC grew its position in Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after buying an additional 970 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.